Ergenekon KARAGÖZ, ALPASLAN TANOĞLU, Vedat TURHAN, Mehmet Burak SELEK, Asım ÜLÇAY, Hakan ERDEM, Ayşe BATIREL

Use of quantitative hepatitis B surface antigen levels in the follow-up of HBV-Infected patients with Genotype D

To determine the role of quantitative HBsAg levels in follow up of chronic HBV treatment and investigate the relationship between qHBsAg, HBV DNA levels and liver histopathology. 74 CHB patients with genotype D visited our Infectious Diseases outpatient clinic were included into the study. Patients were grouped according to treatment status; Group-I (patients new to treatment, 31 patients) and group-II (patients with long-term treatment history). All group-I patients had their serum HBsAg titers (qHBsAg) measured before treatment, at 3 and 6-month time periods after treatment. Group-II consisted of 43 CHB patients who had been on anti-viral treatment for at least 5 years. qHBsAg levels were measured and compared to that of patient in group II. Patients from group I were divided into two groups according to HBeAg positivity. The mean qHBsAg and HBVDNA levels and fibrosis scores were statistically higher (p=0.002, p =0.034, p=0.002) in HBeAg positive patients. For all patients in group-I, a positive correlation was found between qHBsAg and HBV DNA levels before treatment (p=0.003). Serum qHBsAg and HBVDNA levels that were measured before treatment, 3-month and 6-month after treatment were statistically different (p< 0.05) from each other. Group-II patients were classified according to YMDD mutations and virologic breakthrough during treatment. Serum qHBsAg levels of patients with YMDD mutations and virologic breakthrough were found to be statistically higher (p=0.010) than those who did not although these patients were receiving potent antivirals. Quantitative HBsAg levels may differ among chronic HBV patients according to their treatment protocols and duration. In patients who are new to treatment, HBeAg positive patients may have statistically higher levels of qHBsAg. Moreover, this difference was also observed when patient who are new to treatment were compared to those who had been under treatment for a longer time. For clinicians, qHBsAg levels should not be employed only in patients undergoing interferon therapy but also those undergoing antiviral therapy as well..

PDF

___

Karagoz E, Tanoglu A. Clinical Usefulness of HBsAg Quantification in Patients with Chronic Hepatitis B Infection. Hepatitis Monthly. 2017;17:

Li MH, Xie Y, Zhang L, et al. Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a. World J Hepatol. 2016;8:637-43.

Chen CH, Chiu YC, Lu SN, et al. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues. World J Gastroenterol. 2014;20:7686-95.

Vigano M, Lampertico P. Clinical implications of HBsAg quantification in patients with chronic hepatitis B. Saudi J Gastroenterol. 2012;18:81-6.

Azmi AN, Tan SS, Mohamed R. Practical approach in hepatitis B e antigennegative individuals to identify treatment candidates. World J Gastroenterol. 2014;20:12045-55.

Palumbo GA, Scisciani C, Pediconi N, et al. IL6 inhibits HBV transcription by targeting the epigenetic control of the nuclear cccDNA Minichromosome. PloS one. 2015;10:e0142599.

Volz T, Lutgehetmann M, Wachtler P, et al. Impaired intrahepatic hepatitis B virus productivity contributes to low viremia in most HBeAg-negative patients. Gastroenterology. 2007;133:843-52

Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology. 2010;51:193344.

Jaroszewicz J, Calle Serrano B, Wursthorn K, et al. Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)infection: a European perspective. J hepatol. 2010;52:514-22.

Nguyen T, Thompson AJ, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatol. 2010;52:508-13.

Sonneveld MJ, Hansen BE, Piratvisuth T, et al. Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology. 2013;58:872-80.

Brunetto MR, Marcellin P, Cherubini B, et al. Response to peginterferon alfa2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype. J hepatol. 2013;59:1153-9.

Ganji A, Esmaeilzadeh A, Ghafarzadegan K, et al. Correlation between HBsAg quantitative assay results and HBV DNA levels in chronic HBV. Hepat Mon. 2011;11:342-5.

Antaki N, Zeidane N, Alhaj N, et al. HBsAg titers in the different phases of hepatitis B infection in Syrian patients. J Clin Virol. 2012;53:60-4.

Alghamdi A, Aref N, El-Hazmi M, et al. Correlation between hepatitis B surface antigen titers and HBV DNA levels. Saudi J Gastroenterol. 2013;19:252-7.

Demiroren K, Kocamaz H, Dogan Y. The importance of the serum quantitative levels of hepatitis B surface antigen and hepatitis B e antigen in children with chronic hepatitis B. Turk J Gastroenterol. 2015;26:36-41.

Xie QC, H; Zhang, NP; Qi,X; Chen,L;, Guo Sea. Addition of peginterferon ALFA 2B during long term nucleos(t)ide analogue therapy increases HBEAG seroconversion and hbsag decline—week 48 results from a multicenter randomized controlled trial (pegon study). 24th Annual Conference of the Asian Pacific Association for the study of the liver; 2015 Mar 12-15; Istanbul, Turkey: Hepatol Int. 2015 Mar;9(1 Suppl 1):S24; 2015.

Chan HLYK, A;, Papatheodoridis GY, MF; Chien,RN; Kwan,P et al. Characterization of HBsAg decline in the Tenofovir disoproxil fumarate (TDF) and peginterferon alfa 2A (PEG) combination study for chronic hepatitis B (CHB). 24th Annual Conference of the Asian Pacific Association for the study of the liver; 2015 Mar 12-15; Istanbul, Turkey Hepatol Int 2015 Mar;9(1 Suppl 1):S39.

Gramenzi A, Loggi E, Micco L, et al. Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients. J Viral Hepat. 2011;18:e468-74.

Kim BK, Choi SH, Ahn SH, et al. Pre-S mutations of hepatitis B virus affect genome replication and expression of surface antigens. J Gastroenterol Hepatol. 2014;29:843-50.

Zeid WMA, Ramadan DI, Shemis MA. Prevalence of mutations within major hydrophilic region of hepatitis B virus and their correlation with genotypes among chronically infected patients in Egypt. Arab J Gastroenterol. 2016;17:34-40.